1
|
Bomer N, den Hollander W, Ramos YFM, Bos SD, van der Breggen R, Lakenberg N, Pepers BA, van Eeden AE, Darvishan A, Tobi EW, Duijnisveld BJ, van den Akker EB, Heijmans BT, van Roon-Mom WMC, Verbeek FJ, van Osch GJVM, Nelissen RGHH, Slagboom PE, Meulenbelt I. Underlying molecular mechanisms of DIO2 susceptibility in symptomatic osteoarthritis. Ann Rheum Dis 2015; 74:1571-9. [PMID: 24695009 PMCID: PMC4516000 DOI: 10.1136/annrheumdis-2013-204739] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Revised: 03/14/2014] [Accepted: 03/15/2014] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To investigate how the genetic susceptibility gene DIO2 confers risk to osteoarthritis (OA) onset in humans and to explore whether counteracting the deleterious effect could contribute to novel therapeutic approaches. METHODS Epigenetically regulated expression of DIO2 was explored by assessing methylation of positional CpG-dinucleotides and the respective DIO2 expression in OA-affected and macroscopically preserved articular cartilage from end-stage OA patients. In a human in vitro chondrogenesis model, we measured the effects when thyroid signalling during culturing was either enhanced (excess T3 or lentiviral induced DIO2 overexpression) or decreased (iopanoic acid). RESULTS OA-related changes in methylation at a specific CpG dinucleotide upstream of DIO2 caused significant upregulation of its expression (β=4.96; p=0.0016). This effect was enhanced and appeared driven specifically by DIO2 rs225014 risk allele carriers (β=5.58, p=0.0006). During in vitro chondrogenesis, DIO2 overexpression resulted in a significant reduced capacity of chondrocytes to deposit extracellular matrix (ECM) components, concurrent with significant induction of ECM degrading enzymes (ADAMTS5, MMP13) and markers of mineralisation (ALPL, COL1A1). Given their concurrent and significant upregulation of expression, this process is likely mediated via HIF-2α/RUNX2 signalling. In contrast, we showed that inhibiting deiodinases during in vitro chondrogenesis contributed to prolonged cartilage homeostasis as reflected by significant increased deposition of ECM components and attenuated upregulation of matrix degrading enzymes. CONCLUSIONS Our findings show how genetic variation at DIO2 could confer risk to OA and raised the possibility that counteracting thyroid signalling may be a novel therapeutic approach.
Collapse
Affiliation(s)
- Nils Bomer
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- IDEAL, The Netherlands
| | | | | | - Steffan D Bos
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- Genomics Initiative, sponsored by the NCHA, Leiden, The Netherlands
| | | | - Nico Lakenberg
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
| | - Barry A Pepers
- Department of Human Genetics, LUMC, Leiden, The Netherlands
| | | | - Arash Darvishan
- Department of Imaging & BioInformatics, LIACS, Leiden, The Netherlands
| | - Elmar W Tobi
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- IDEAL, The Netherlands
| | | | - Erik B van den Akker
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- The Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands
| | - Bastiaan T Heijmans
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- Genomics Initiative, sponsored by the NCHA, Leiden, The Netherlands
| | | | - Fons J Verbeek
- Department of Imaging & BioInformatics, LIACS, Leiden, The Netherlands
| | - Gerjo J V M van Osch
- Department of Orthopaedics, Erasmus MC, Rotterdam, The Netherlands
- Deptartment of Otorhinolaryngology, Erasmus MC, Rotterdam, The Netherlands
| | | | - P Eline Slagboom
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- IDEAL, The Netherlands
- Genomics Initiative, sponsored by the NCHA, Leiden, The Netherlands
| | - Ingrid Meulenbelt
- Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands
- Genomics Initiative, sponsored by the NCHA, Leiden, The Netherlands
| |
Collapse
|